HistoWiz

HistoWiz

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8.5M

Overview

Founded in 2013, HistoWiz has established itself as a leading service provider in the research histopathology and digital pathology space, leveraging automation to deliver results in as few as three days. Its core offering integrates traditional lab services (histology, IHC/IF) with a digital platform for slide management, analysis, and collaboration, backed by a large network of board-certified pathologists. The company targets academic, biotech, and pharmaceutical researchers, aiming to accelerate preclinical research and drug development through faster, data-rich histopathology workflows.

DiagnosticsDigital Health

Technology Platform

PathologyMap™: A cloud-based digital pathology platform for whole slide image management, viewing, annotation, sharing, and AI-driven analysis/QC tools, integrated with automated histology lab services.

Funding History

2
Total raised:$8.5M
Series A$7M
Seed$1.5M

Opportunities

The global shift to digital pathology and demand for faster preclinical data create a large market for integrated service-platform models.
HistoWiz's aggregated dataset on PathologyMap™ presents a unique asset for developing and commercializing AI-based QC and analysis tools, potentially opening new software revenue streams.

Risk Factors

Operational risk is high, as reputation depends on consistently delivering rapid, high-quality, GLP-compliant results.
Competition from other CROs and in-house cores could pressure pricing.
The value of its data platform depends on successful AI tool development and navigating data privacy concerns.

Competitive Landscape

HistoWiz competes with other specialized preclinical histology CROs (e.g., Charles River Laboratories' pathology services, Labcorp's preclinical services), academic core facilities, and standalone digital pathology software vendors. Its key differentiators are its guaranteed 3-day turnaround, integrated digital platform, and extensive pathologist network.